Investor Relations 2021
Pipeline
✓ Aiming to launch at least 1 biosimilar every year by 2030
Product
Name
Reference
Drug
Manufacturer Indications
Global
Market size
($bn)
US
RemsimaⓇ SC
Celltrion
Autoimmune
Disease
48.5
In Phase 3
EU
All Indication Approved
(Jul.2020,
Pediatric usage non-included)
Received European
Commission Approval
(Feb.2021)
In Global Phase 3 Clinical Trials
(Aiming to complete by 1H21)
YuflymaⓇ
HumiraⓇ
(Adalimumab)
AbbVie
Autoimmune
Disease
Preparing Application
30.4
Submission
CT-P16
Avastin®
(Bevacizumab)
Roche
Colorectal
Cancer, etc.
6.1
CT-P39
XolairⓇ
(Omalizumab)
Allergic Asthma,
Genentech
3.3
CIU
In Global Phase 3 Clinical Trials
(Jul.2020~)
CT-P43
StelaraⓇ
(Ustekinumab)
Johnson &
Johnson
Autoimmune
10.9
Disease
In Global Phase 3 Clinical Trials
(Sep.2020~)
CT-P41
ProliaⓇ
(Denosumab)
Amgen
Osteoporosis
5.2
In Global Phase 3 Clinical Trials
(Sep.2020~)
CT-P42
EyleaⓇ
(Aflibercept)
Bayer &
Regeneron
Macular
Degeneration
6.1
In Global Phase 3 Clinical Trials
(Jan.2021~)
Note: global market size is as of 2020
Source: IQVIA
Investor Relations 2021 14View entire presentation